Skip to search formSkip to main contentSkip to account menu

solanezumab

Known as: Immunoglobulin G1, anti-(human beta-amyloid peptide) (humanized monoclonal LY2062430 heavy chain, disulfide with humanized monoclonal LY2062430 light chain, dimer) 
A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Solanezumab recognizes and… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

LY 2062430
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Is Now the Time for Combination Therapies for Alzheimer Disease?
In this issue, Gauthier and colleagues from the European Union-North America Clinical Trials in Alzheimer Disease Task Force (EU… 
2017
2017
Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease
ObjectiveA delayed-start design has been proposed to assess a potential disease-modifying effect in investigational drugs for… 
Review
2015
Review
2015
Alzheimer's disease and other dementias: advances in 2014
2015
2015
NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost.
At the Alzheimer's Association International Conference in Washington, D.C., last week, researchers expressed cautious optimism… 
2015
2015
Alzheimer disease: Solanezumab—prospects for meaningful interventions in AD?
A treatment trial of the monoclonal anti-amyloid antibody solanezumab showed slight benefits in people with dementia due to mild… 
2015
2015
Alzheimer antibody drugs show questionable potential
Amyloid-targeted antibodies seem to have a small clinical benefit in patients with mild Alzheimer disease, but issues with the… 
Highly Cited
2014
Highly Cited
2014
Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
To the Editor: Salloway et al. (Jan. 23 issue)1 report on two trials of bapineuzumab in mild-tomoderate Alzheimer’s disease, and… 
2013
2013
2012: A watershed year for Alzheimer’s disease research
Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from… 
2012
2012
Genentech's Alzheimer's antibody trial to study disease prevention
2012
2012
Certain new aspects of etiology and pathogenesis of Alzheimer’s disease
The research focuses on the possibility of early detection of AD-specific vascular and atrophic brain changes in families which… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)